Compounds as anti-tubercular agents
AssigneesSphaera Pharma Pvt. Ltd., Drug Discovery Research Centre
InventorsSundeep Dugar, Dinesh Mahajan, Santosh Kumar Rai, Kanury Rao, Varshneya Singh
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds of formula (1): The present invention also discloses compounds of formula (1) along with other pharmaceutical acceptable excipients and use of the compounds as anti-tubercular agents.
Claims9
A method for treatment of an infection caused by resistant or non-resistant Mycobacterium tuberculosis, comprising administering to a subject in need thereof a compound of structural Formula (1), including its salts, hydrates or stereoisomers:
- wherein
- X is O, NH or N(alkyl);
- R1 and R2 are independently hydrogen, but with the proviso that R1 and R2 are not both hydrogen, deuterium, hydroxyl, C1-10 straight chain or branched chain alkyl, 3-7 membered cycloalkyl, C1-6alkoxy, aryl, amino, NH(alkyl), N(alkyl)2,OCOR5, heteroaryl containing 1-3 heteroatoms selected from the group consisting of O, N and S;
- or R1 and R2 may combined to form an aryl or a heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of O, N and S;
- R3 is a non-aromatic heterocyclic ring or fused heterocyclic ring selected from:
- X may in conjunction with R3 form a 5-7 membered heterocyclic ring comprising 1-3 heteroatoms selected from group consisting of N, O and S, wherein the heterocyclic ring be further substituted with one or more lower alkyl groups, halogens, amino, NH(alkyl), N(alkyl)2, NH-aralkyl;
- R4 is a hydrogen, lower straight chain or branched alkyl, halogen, deuterium, C1-6alkoxy, amino, NH(alkyl), N(alkyl)2, —COOR8, or CONR8R9;
- R5 is hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, amino, NH(alkyl), or N(alkyl)2;
- R6 and R7 are independently selected from the group consisting of hydrogen, C1-10alkyl, —COR8, —CH2OCOR8, —CH2OCONHR8R9, —COOR8, —CONR8R9, —SO2R8, aryl, and aralkyl;
- R8 and R9 are independently selected from the group consisting of hydrogen, and C1-6 straight chain or branched chain alkyl;
- and
- n is 1, 2, or 3.
A method for treatment of an infection caused by resistant or non-resistant Mycobacterium tuberculosis, comprising inhibiting GPR109A in the Mycobacterium tuberculosis by a compound of structural Formula (1), including its salts, hydrates or stereoisomers:
- wherein
- X is O, NH or N(alkyl);
- R1 and R2 are independently hydrogen, but with the proviso that R1 and R2 are not both hydrogen, deuterium, hydroxyl, C1-10 straight chain or branched chain alkyl, 3-7 membered cycloalkyl, C1-6alkoxy, aryl, amino, NH(alkyl), N(alkyl)2,OCOR5, heteroaryl containing 1-3 heteroatoms selected from the group consisting of O, N and S;
- or R1 and R2 may combined to form an aryl or a heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of O, N and S;
- R3 is a non-aromatic heterocyclic ring or fused heterocyclic ring selected from:
- X may in conjunction with R3 form a 5-7 membered heterocyclic ring comprising 1-3 heteroatoms selected from group consisting of N, O and S, wherein the heterocyclic ring be further substituted with one or more lower alkyl groups, halogens, amino, NH(alkyl), N(alkyl)2, NH-aralkyl;
- R4 is a hydrogen, lower straight chain or branched alkyl, halogen, deuterium, C1-6 alkoxy, amino, NH(alkyl), N(alkyl)2, —COOR8, or CONR8R9;
- R5 is hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, amino, NH(alkyl), or N(alkyl)2;
- R6 and R7 are independently selected from the group consisting of hydrogen, C1-10 alkyl, —COR8, —CH2OCOR8, —CH2OCONHR8R9, —COOR8, —CONR8R9, —SO2R8, aryl, and aralkyl;
- R8 and R9 are independently selected from the group consisting of hydrogen, and C1-6 straight chain or branched chain alkyl;
- and
- n is 1, 2, or 3.
A method for treatment of resistant or non-resistant tuberculosis infection in a subject in need thereof, comprising inhibiting GPR109A in the subject by a compound of structural Formula (1), including its salts, hydrates or stereoisomers:
- wherein
- X is O, NH or N(alkyl);
- R1 and R2 are independently hydrogen, but with the proviso that R1 and R2 are not both hydrogen, deuterium, hydroxyl, C1-10 straight chain or branched chain alkyl, 3-7 membered cycloalkyl, C1-6alkoxy, aryl, amino, NH(alkyl), N(alkyl)2,OCOR5, heteroaryl containing 1-3 heteroatoms selected from the group consisting of O, N and S;
- or R1 and R2 may combined to form an aryl or a heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of O, N and S;
- R3 is a non-aromatic heterocyclic ring or fused heterocyclic ring selected from:
- X may in conjunction with R3 form a 5-7 membered heterocyclic ring comprising 1-3 heteroatoms selected from group consisting of N, O and S, wherein the heterocyclic ring be further substituted with one or more lower alkyl groups, halogens, amino, NH(alkyl), N(alkyl)2, NH-aralkyl;
- R4 is a hydrogen, lower straight chain or branched alkyl, halogen, deuterium, C1-6 alkoxy, amino, NH(alkyl), N(alkyl)2, —COOR8, or CONR8R9;
- R5 is hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, amino, NH(alkyl), or N(alkyl)2;
- R6 and R7 are independently selected from the group consisting of hydrogen, C1-10 alkyl, —COR8, —CH2OCOR8, —CH2OCONHR8R9, —COOR8, —CONR8R9, —SO2R8, aryl, and aralkyl;
- R8 and R9 are independently selected from the group consisting of hydrogen, and C1-6 straight chain or branched chain alkyl;
- and
- n is 1, 2, or 3.
Dependencies are inferred from the claim text.